REGN
Regeneron Pharmaceuticals, Inc.Healthcare · $78.3B market cap
Verdict
Share price
$735.20
close of Oct 3, 2026
Fair value
$738.00
Sticker Price
Payback Price
$295.20
buy price
REGN is Fairly Valued: at $735.20 it's right at its fair value of $738.00. Its buy price (Payback Price) is $295.20, 60% below today's price. Business quality is strong: all 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 6% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
5 of 5 clear the 10% bar. What are the Big Five?
Follow REGN
Get notified when it reaches its buy price of $295.20. Free.
Create a free accountSuperinvestors
3 of the investors we track hold REGN. In Q2 2026, 1 added and 1 trimmed. Who we track
Insider activity
Since Jul 2, 2026: no open-market purchases, 6 sales worth $3.4M and 7 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
McCourt Marion
EVP Commercial · 2026-09-03
Sold
$970K
Guarini Kathryn
director · 2026-09-02
Sold
$340K
McCourt Marion
EVP Commercial · 2026-09-02
Sold
$1.0M
Zoghbi Huda Y
director · 2026-08-10
Sold
$640K
Guarini Kathryn
director · 2026-08-10
Sold
$320K
Show all 6 salesShow fewer
RYAN ARTHUR F
director · 2026-07-02
Sold
$130K
Other filings
Guarini Kathryn
director · 2026-09-02
Option exercise
$288K
LAROSA JOSEPH J
EVP General Counsel and Secret · 2026-08-19
Tax withholding
$7.5M
LAROSA JOSEPH J
EVP General Counsel and Secret · 2026-08-19
Option exercise
$4.7M
Fenimore Christopher R.
EVP Finance CFO · 2026-08-18
Tax withholding
$3.7M
Fenimore Christopher R.
EVP Finance CFO · 2026-08-18
Option exercise
$2.4M
Show all 7 other filingsShow fewer
Zoghbi Huda Y
director · 2026-08-10
Option exercise
$301K
Guarini Kathryn
director · 2026-08-10
Option exercise
$288K
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works